The latest price target for Akari Therapeutics (NASDAQ:AKTX) was reported by HC Wainwright & Co. on December 5, 2022. The analyst firm set a price target for $1.50 expecting AKTX to rise to within 12 months (a possible 19.17% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Akari Therapeutics (NASDAQ:AKTX) was provided by HC Wainwright & Co., and Akari Therapeutics initiated their buy rating.

There is no last upgrade for Akari Therapeutics

There is no last downgrade for Akari Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akari Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akari Therapeutics was filed on December 5, 2022 so you should expect the next rating to be made available sometime around December 5, 2023.

While ratings are subjective and will change, the latest Akari Therapeutics (AKTX) rating was a initiated with a price target of $0.00 to $1.50. The current price Akari Therapeutics (AKTX) is trading at is $1.26, which is within the analyst’s predicted range.